Event
Bioengineering Seminar Series: Mitchell Ho
Friday, April 29, 2016
9:00 a.m.-10:15 a.m.
Pepco Room (1105), Jeong H. Kim Engineering Building
Dr. Christopher Jewell
cmjewell@umd.edu
Mitchell Ho
Senior Investigator
Laboratory of Molecular Biology
NCI/NIH
Novel Antibodies Targeting Glypican-3 and Mesothelin for Cancer Therapies
Dr. Ho's lab at the National Cancer Institute (NCI) uses antibody engineering to generate novel therapeutics for the treatment of cancers. His lab has pioneered the production of inhibitory antibodies that recognize tumor specific heparan sulfate proteoglycans. Through multi-institutional collaborations, he has constructed heavy-chain antibodies with the unique ability to seek out functional cavities and poorly exposed epitopes associated with tumors. Dr. Ho’s research has combined cutting edge phage display technologies with innovative functional screening techniques to facilitate the production of next generation therapeutics. His inhibitory antibodies have been shown to inactivate the Wnt/Yap signaling pathway known to be important for cancer pathogenesis. The primary focus is glypican-3 which is mainly expressed in hepatocellular carcinoma. Additionally, his lab is also interested in mesothelin as a target for treating mesothelioma and other tumors.
